Reduced circulating Mig-6 levels are associated with dysglycemia in metabolic dysfunction associated steatotic liver disease (MASLD)
Introduction Type 2 diabetes mellitus (T2D) accelerates the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) to hepatic fibrosis, and a subset of MASLD subjects has T2D. Identification of molecular mediators linking T2D and MASLD progression remains unmet. Studies revealed patients with steatohepatitis have lower hepatic Mitogen inducible gene-6 (Mig-6) expression, and Mig-6 gene silencing […]
